Rutgers scientists have developed a new approach to stopping viral infections: a so-called live-attenuated, replication-defective DNA virus vaccine that uses a compound known as centanamycin to generate an altered virus for ...
Nov 18, 2022
0
57
A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was ...
Nov 4, 2022
0
33
Most research on immunity to the SARS-CoV-2 virus and COVID-19 vaccine development has focused on antibody responses to the spike protein and other viral surface proteins. But antibodies that recognize the virus's internal ...
Jun 24, 2022
0
154
Influenza is a major global public health concern and a huge economic burden to societies. Seasonal influenza epidemics afflict between 13 to 100 million individuals annually, including three to five million cases of severe ...
Mar 30, 2022
0
157
Respiratory syncytial virus (RSV) is a leading cause of severe acute lower respiratory tract infections (LRTIs) among infants globally, and a prominent contributor to common non-severe infections that account for high volumes ...
Mar 14, 2022
0
55
A new genomics study led by the University of Liverpool will help guide the development and use of vaccines against a globally leading cause of severe diarrhea in children: shigella.
Feb 1, 2022
0
40
When scientists were developing a vaccine against COVID-19, a key worry was the potential to cause disease enhancement. It's a complication that occurs when a vaccine does the opposite of what it's intended to do and instead ...
Oct 25, 2021
0
436
A team of researchers affiliated with multiple institutions in the U.S. and one in the U.K. has found that administering the AstraZeneca COVID-19 vaccine intranasally to infected hamsters and monkeys reduced viral loads in ...
According to a new study co-authored by Yale's Mushfiq Mobarak and Saad Omer, COVID-19 vaccine acceptance is significantly higher in low- and middle-income countries than wealthy ones. The results suggest that prioritizing ...
Jul 21, 2021
0
255
A KAIST immunology research team found that most convalescent patients of COVID-19 develop and maintain T cell memory for over 10 months regardless of the severity of their symptoms. In addition, memory T cells proliferate ...
Jul 5, 2021
0
170
